Publications by authors named "J D Morell"
Probing the reactivity of a transient Al(I) species with substituted arenes.
Chem Commun (Camb)
November 2024
With only a handful of compounds known, opportunities to explore the structure and reactivity of dialumenes and related dialumene adducts have been limited. For the first time, a series of dialumene-arene adducts have been synthesised; adduct formation has been probed experimentally and through DFT, and their reactivity investigated.
View Article and Find Full Text PDFArticle Synopsis
- There is limited real-world data on COVID-19 management in patients with hematologic diseases (HD) during the Omicron variant phase, prompting this study to evaluate clinical outcomes and risk factors.
- A review of 692 HD patients from December 2021 to May 2023 revealed that a significant portion went untreated, with a low COVID-19 mortality rate, while specific antiviral treatments were linked to varying outcomes based on disease severity.
- Key findings indicate that older age, certain treatment procedures, and incomplete vaccinations heightened the risk of severe COVID-19 outcomes, emphasizing the need for complete vaccinations to improve management in this vulnerable population.
This retrospective cohort study found that implementing source-specific antibiotic order sets for sepsis in the emergency department increased appropriate empiric antibiotic selection from 51% to 74% ( = .01).
View Article and Find Full Text PDFBackground: Current practice for patients with suspected or confirmed upper gastrointestinal bleeding (GIB) is to utilize a proton pump inhibitor (PPI) bolus followed by a continuous infusion for 72 hours. Literature has shown similar outcomes with intermittent bolus dosing compared to continuous infusion. Substitution would lead to reduced costs and utilization of resources.
View Article and Find Full Text PDFArticle Synopsis
- This study examined the effects of two antiviral treatments, remdesivir and nirmatrelvir/ritonavir, on hematological patients infected with SARS-CoV-2 during the Omicron period, using data from a Spanish registry collected from December 2021 to April 2023.
- Out of 466 patients analyzed, those treated with nirmatrelvir/ritonavir had a low COVID-19-related mortality rate of 1.3%, primarily used in mild cases, while remdesivir, used for moderate to severe cases, showed a higher mortality rate of 9%.
- The study found that male gender was linked to lower mortality risk while corticosteroid use and co-infections increased risk, and highlighted that